title: Plasma 3-nitrotyrosine and outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric oxide.
abstract: Plasma protein levels of 3-nitrotyrosine and 3-chlorotyrosine were measured by LC-MS/MS at 0 and 72 h after the initiation of inhaled nitric oxide (INO) at 20 ppm in 22 prematurely born infants with clinically documented bronchopulmonary dysplasia. Infants were classified at the time of hospital discharge as either "off mechanical ventilation," "on mechanical ventilation," or "expired/organ failure." These outcomes were tested for association with changes in plasma levels of 3-nitrotyrosine and 3-chlorotyrosine and selected clinical risk factors. Infants whose 3-nitrotyrosine levels decreased over the 72 h period were more likely to wean off of mechanical ventilation (p =.03). There was no significant association between changes in 3-chlorotyrosne levels and outcome. After controlling for other variables, an odds ratio of 8.3 (95% CI: 1.3-54.4) for improved outcomes was observed if the 3-nitrotyrosine levels decreased. These data suggest that nitrative and oxidative stress may be related to the severity of lung disease and, consequentially, the overall outcome in this select group of infants with severe bronchopulmonary dysplasia.
authors.affiliation: Division of Neonatology, Children's Hospital of Philadelphia, PA 19104, USA.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Lorch
authors.forename: Beverly A
authors.initials: BA
authors.lastname: Banks
authors.forename: Jason
authors.initials: J
authors.lastname: Christie
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Merrill
authors.forename: John
authors.initials: J
authors.lastname: Althaus
authors.forename: Keri
authors.initials: K
authors.lastname: Schmidt
authors.forename: Philip L
authors.initials: PL
authors.lastname: Ballard
authors.forename: Harry
authors.initials: H
authors.lastname: Ischiropoulos
authors.forename: Roberta A
authors.initials: RA
authors.lastname: Ballard
mesh_terms: D000280:Administration, Inhalation; D001724:Birth Weight; D001997:Bronchopulmonary Dysplasia / Q000097:blood* / Q000188:drug therapy*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016015:Logistic Models; D008297:Male; D013058:Mass Spectrometry; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000097:blood*; D012122:Ventilators, Mechanical
chemical_list: D009569:Nitric Oxide; C002744:3-nitrotyrosine; D014443:Tyrosine; C087259:3-chlorotyrosine